Inhibrx Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INXB research report →
Price Chart
About the company
Inhibrx Biosciences, Inc. operates as a clinical-stage biopharmaceutical entity, primarily focused on developing advanced biologic treatments for critical, life-threatening medical conditions. Key assets within its development pipeline include: INBRX-109, a tetravalent investigational therapy, is progressing through Phase 2 clinical trials.
- CEO
- Mark Paul Lappe
- IPO
- 2018
- Employees
- 166
- HQ
- La Jolla, CA, US
Get TickerSpark's AI analysis on INXB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $225.87M
- P/E
- -11.17
- PEG
- -0.60
- P/S
- 0.00
- P/B
- -29.33
- EV/EBITDA
- -11.01
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 1893.60%
- ROIC
- -99.35%
- 52W High
- $18.95
- 52W Low
- $12.95
- 50D MA
- $16.45
- 200D MA
- $16.45
- Beta
- 2.88
- RSI (14)
- 49
- Avg Volume
- 440.58K
No earnings-call transcripts are available for INXB yet.
- Free Float
- 0.0%
- Shares Outstanding
- 14.24M
- Float Shares
- 0
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 29, 24 | VIKING GLOBAL INVESTORS LP | other | 0 |
| May 29, 24 | VIKING GLOBAL INVESTORS LP | other | 0 |
| May 29, 24 | VIKING GLOBAL INVESTORS LP | other | 0 |
| May 29, 24 | VIKING GLOBAL INVESTORS LP | other | 259,692 |
| May 30, 24 | Vuori Kristiina MD | other | 30,000 |
| May 30, 24 | MANHARD KIMBERLY | other | 30,000 |
| May 29, 24 | Lappe Mark | other | 621,548 |
| May 30, 24 | Lappe Mark | other | 300,000 |
| May 29, 24 | Lappe Mark | other | 125,000 |
| May 29, 24 | Lappe Mark | other | 14,865 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our INXB coverage
Recent articles, reports, and earnings notes.
No research on INXB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INXB report →